Stevanato Group (NYSE:STVN – Get Free Report) and SI-BONE (NASDAQ:SIBN – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.
Profitability
This table compares Stevanato Group and SI-BONE’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Stevanato Group | 10.47% | 9.86% | 5.79% |
| SI-BONE | -23.82% | -22.51% | -16.53% |
Risk & Volatility
Stevanato Group has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Stevanato Group | $1.17 billion | 5.18 | $157.62 million | €0.47 ($0.49) | 42.77 |
| SI-BONE | $138.89 million | 5.01 | -$43.34 million | ($0.92) | -18.03 |
Stevanato Group has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
98.1% of SI-BONE shares are owned by institutional investors. 0.7% of Stevanato Group shares are owned by insiders. Comparatively, 3.9% of SI-BONE shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Stevanato Group and SI-BONE, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Stevanato Group | 0 | 1 | 5 | 0 | 2.83 |
| SI-BONE | 0 | 0 | 6 | 0 | 3.00 |
SI-BONE has a consensus price target of $23.00, suggesting a potential upside of 38.64%. Given SI-BONE’s stronger consensus rating and higher possible upside, analysts plainly believe SI-BONE is more favorable than Stevanato Group.
Summary
Stevanato Group beats SI-BONE on 8 of the 14 factors compared between the two stocks.
About Stevanato Group
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
About SI-BONE
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.
